UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus
UBS Initiates Merus(MRUS.US) With Buy Rating, Announces Target Price $72
Investing in Merus (NASDAQ:MRUS) Five Years Ago Would Have Delivered You a 227% Gain
Merus Is Maintained at Buy by Guggenheim
Merus Analyst Ratings
Express News | Merus NV : Guggenheim Raises Target Price to $111 From $93
BMO Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $95
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
Buy Rating Affirmed for Merus on Strong Clinical Trial Progress and Competitive Positioning
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination With Pembrolizumab in 1L R/m HNSCC
TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth
Truist Financial Maintains Merus(MRUS.US) With Buy Rating
Truist Financial analyst Asthika Goonewardene maintains $Merus(MRUS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 32.7% and a total average return of -5.0%
Truist Financial Gives a Buy Rating to Merus (MRUS)
NRG Fusion Market to Grow at a CAGR of 15% Due to Expected First Launch of Merus' Zenocutuzumab and Increased Adoption of NRG1 Fusion Biomarker Testing During the Study Period (2020-2034) | DelveInsight
Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine's RNA Platform
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
LifeSci Capital analyst Charles Zhu maintains $Merus(MRUS.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 40.4% and a
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Raises Target Price to $100
LifeSci Capital analyst Charles Zhu maintains $Merus(MRUS.US)$ with a buy rating, and adjusts the target price from $48 to $100.According to TipRanks data, the analyst has a success rate of 40.4%
Buy Rating on Merus Backed by Strong Clinical Advantages and Market Positioning